India, June 19 -- This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts.
Positive clinical readouts spanning therapeutic areas include Prader-Willi syndrome, Chronic Lymphocytic Leukaemia, Angioedema, and Chronic Spontaneous Urticaria, bolstering innovation in therapeutic breadth.
Let's unpack the specifics.
FDA Approvals
Spero's Oral Antibiotic Milestone
Spero Therapeutics (SPRO)and GSK plc (GSK) announced FDA approval of Utebzi (tebipenem pivoxil), the first oral carbapenem for complicated urinary tract infections in adults with limited treatment options. The decision follows a prior CRL in 2022 and a resubmission backed by...